Overall Survival of Men with Metachronous Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy

Ian D. Davis

Overall Survival of Men with Metachronous Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy - Beyond the Abstract

Eastern Health Clinical School Research

Research output: Other contribution › Other › peer-review

Abstract

Evidence has been presented in the last seven years that has transformed the management of metastatic hormone-sensitive prostate cancer (mHSPC). The principles of management for about seven decades had fundamentally been around testosterone suppression. We now have clear data for the benefit of docetaxel (CHAARTED, STAMPEDE), abiraterone (LATITUDE, STAMPEDE), apalutamide (TITAN), and enzalutamide (ARCHES, ENZAMET).

Original language	English
Type	Editorial commentary
Media of output	Online
Publisher	UroToday - GU Oncology Today
Publication status	Published - 17 Jun 2021

Keywords

prostate cancer
Enzalutamide
Androgen deprivation therapy
hormone sensitive
Survival

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

http://urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/130307-overall-survival-of-men-with-metachronous-metastatic-hormone-sensitive-prostate-cancer-treated-with-enzalutamide-and-androgen-deprivation-therapy-beyond-the-abstract.html

1 Article

Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy
Sweeney, C. J., Martin, A. J., Stockler, M. R., Begbie, S., Chi, K. N., Chowdhury, S., Coskinas, X., Frydenberg, M., Hague, W. E., Horvath, L. G., Joshua, A. M., Lawrence, N. J., Marx, G. M., McCaffrey, J., McDermott, R., McJannett, M., North, S. A., Parnis, F., Parulekar, W., Pook, D. W., & 13 othersReaume, M. N., Sandhu, S. K., Tan, A., Tan, T. H., Thomson, A., Tu, E., Vera-Badillo, F., Williams, S. G., Yip, S., Zhang, A. Y., Zielinski, R. R., Davis, I. D. & for the ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Sept 2021, In: European Urology. 80, 3, p. 275-279 5 p.
Research output: Contribution to journal › Article › Research › peer-review

30 Citations (Scopus)

Cite this

Davis, I. D. (2021, Jun 17). Overall Survival of Men with Metachronous Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy - Beyond the Abstract. UroToday - GU Oncology Today. http://urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/130307-overall-survival-of-men-with-metachronous-metastatic-hormone-sensitive-prostate-cancer-treated-with-enzalutamide-and-androgen-deprivation-therapy-beyond-the-abstract.html

@misc{83947f4f5749457ea3ee7fbbe2e92ece,

title = "Overall Survival of Men with Metachronous Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy - Beyond the Abstract",

abstract = "Evidence has been presented in the last seven years that has transformed the management of metastatic hormone-sensitive prostate cancer (mHSPC). The principles of management for about seven decades had fundamentally been around testosterone suppression. We now have clear data for the benefit of docetaxel (CHAARTED, STAMPEDE), abiraterone (LATITUDE, STAMPEDE), apalutamide (TITAN), and enzalutamide (ARCHES, ENZAMET).",

keywords = "prostate cancer, Enzalutamide, Androgen deprivation therapy, hormone sensitive, Survival",

author = "Davis, {Ian D.}",

year = "2021",

month = jun,

day = "17",

language = "English",

publisher = "UroToday - GU Oncology Today",

type = "Other",

}

Davis, ID 2021, Overall Survival of Men with Metachronous Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy - Beyond the Abstract. UroToday - GU Oncology Today. <http://urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/130307-overall-survival-of-men-with-metachronous-metastatic-hormone-sensitive-prostate-cancer-treated-with-enzalutamide-and-androgen-deprivation-therapy-beyond-the-abstract.html>

TY - GEN

T1 - Overall Survival of Men with Metachronous Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy - Beyond the Abstract

AU - Davis, Ian D.

PY - 2021/6/17

Y1 - 2021/6/17

N2 - Evidence has been presented in the last seven years that has transformed the management of metastatic hormone-sensitive prostate cancer (mHSPC). The principles of management for about seven decades had fundamentally been around testosterone suppression. We now have clear data for the benefit of docetaxel (CHAARTED, STAMPEDE), abiraterone (LATITUDE, STAMPEDE), apalutamide (TITAN), and enzalutamide (ARCHES, ENZAMET).

AB - Evidence has been presented in the last seven years that has transformed the management of metastatic hormone-sensitive prostate cancer (mHSPC). The principles of management for about seven decades had fundamentally been around testosterone suppression. We now have clear data for the benefit of docetaxel (CHAARTED, STAMPEDE), abiraterone (LATITUDE, STAMPEDE), apalutamide (TITAN), and enzalutamide (ARCHES, ENZAMET).

KW - prostate cancer

KW - Enzalutamide

KW - Androgen deprivation therapy

KW - hormone sensitive

KW - Survival

M3 - Other contribution

PB - UroToday - GU Oncology Today

ER -